Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. It offers Midazolam for epileptic seizure; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster headaches, as well as Hydrocortisone for acute adrenal crisis and Methotrexate for the treatment of rheumatoid arthritis. In addition, the company is developing ZEPIZURE, an emergency treatment for managing epileptic seizures. The company was incorporated in 2001 and is based in Dijon, France.
Frequently asked questions
What sector does Crossject (ALCJ) operate in?
Crossject belongs to the Healthcare sector and operates in the Medical Instruments & Supplies industry.
What is Crossject (ALCJ) current stock price?
As of the latest data, Crossject stock price is €1.43, with a previous close of €1.43.
What is Crossject (ALCJ) current market capitalization?
Crossject market cap is approximately 85.96 million.
What is Crossject (ALCJ) Earnings Per Share (EPS)?
The trailing EPS is -€0.19, and the forward EPS is €0.52.
Does Crossject (ALCJ) pay dividends?
No. Crossject does not pay a dividend.
What is Crossject (ALCJ) beta (volatility) score?
Crossject has a beta of 0.496, indicating lower volatility than the overall market.
